Fryns Microphthalmia Syndrome

Fryns microphthalmia syndrome describes babies born with a combination of features classically seen in Fryns syndrome—a rare, usually autosomal-recessive condition—with severe? eye underdevelopment (microphthalmia) or absence of an eye (anophthalmia). The Fryns picture often includes a hole in the diaphragm? before birth (congenital? diaphragmatic hernia), under-developed lungs, distinctive facial features, short nails or fingertip bones, and differences in many organs. When the eye is very small or absent, vision is severely affected and the face and eye socket may grow differently; early eye-socket expansion and prosthetic planning help growth and appearance. Survival and long-term outcomes depend mainly on the lung and diaphragm problems and on other organ differences that may occur with the eye findings. PMC+3NCBI+3MedlinePlus+3

Scientists now recognize that several genes involved in early body and eye formation can lead to a Fryns-like picture, and biallelic variants in PIGN (a gene used to build GPI-anchors on cell surfaces) are a confirmed cause in some families once labeled Fryns syndrome. Eye malformations such as microphthalmia/anophthalmia are genetically diverse (dozens of genes like SOX2, OTX2, PAX6, CHD7 and others), and the same gene can cause different severities in the eye and body. That is why modern care includes genomic testing and careful genetic counseling for families. BioMed Central+3GIM Journal+3PMC+3

Fryns microphthalmia syndrome” is used as a synonym for Anophthalmia-plus syndrome in rare-disease catalogs. Separately, Fryns syndrome (without the word “microphthalmia”) is a different, broader condition best known for congenital diaphragmatic hernia but it can also include microphthalmia—this sometimes causes confusion? in names. MedlinePlus+3Orpha+3Orpha+3

Other names

• Anophthalmia-plus syndrome

• Microphthalmia with facial clefting

• Fryns microphthalmia syndrome (terminology used in Orphanet/MONDO)

• Historical labels in reports may include Fryns anophthalmia syndrome or Leichtman-Wood-Rohn syndrome. Orpha+1

Types

Because formal genetic sub-types are not fixed yet, clinicians often describe clinical? patterns rather than official “types”:

1. Eye-severity pattern:

   • Anophthalmia (eyes absent clinically)

   • Severe microphthalmia (very small eyes)

   • Microphthalmia with coloboma/glaucoma/cornea? clouding (some reports) PubMed+1

2. Laterality: Bilateral? (both eyes) vs unilateral? (one eye), though bilateral is frequent in published cases. PubMed

3. Facial-cleft pattern:

   • Cleft lip with/without cleft palate

   • Cleft palate only

   • Wider facial clefts/frontonasal clefting in a minority; these overlap with ALX1-related frontonasal dysplasia phenotypes. Orpha+1

4. Systemic?-involvement pattern:

   • Ocular-dominant (mainly eye + cleft)

   • Multisystem (eye/cleft + spine/brain/renal?/endocrine or airway features) as summarized in rare-disease databases and case reports. MalaCards

Causes

Key idea: For Fryns microphthalmia (Anophthalmia-plus) syndrome, the most supported cause is genetic and likely autosomal recessive, but the exact gene is not yet established, and doctors often evaluate genes known to cause anophthalmia/microphthalmia with facial clefts. Below are causes and contributors doctors consider (some are general to the MAC spectrum—microphthalmia/anophthalmia/coloboma—used in workup and counseling):

1. Autosomal-recessive inheritance (undetermined gene in APS) – Several families suggest recessive transmission; the specific gene for APS is not yet defined. Wiley Online Library+1

2. ALX1 gene variants – Can cause severe microphthalmia with facial clefting/frontonasal dysplasia, overlapping the APS picture. PMC

3. SOX2 variants – A leading cause of anophthalmia/microphthalmia syndromes; included in differential panels. MedlinePlus+1

4. OTX2 variants – Transcription factor important for eye development; linked to MAC spectrum. MedlinePlus

5. PAX6 variants – Master eye-development gene; MAC spectrum. MedlinePlus

6. ALDH1A3 variants – Retinoic-acid pathway; a recognized MAC gene. MedlinePlus

7. STRA6/RBP4 pathway – Vitamin A transport/signaling; associated with eye malformations and sometimes facial anomalies. MedlinePlus

8. BCOR variants – Cause Lenz microphthalmia syndrome (X-linked), a key differential. NORD

9. CHD7 variants – CHARGE syndrome (includes coloboma/ear/choanal defects); in the differential. MedlinePlus

10. SMOC1 variants – Linked to microphthalmia with limb anomalies; part of MAC gene panels. Breda Genetics

11. FOXE3, BMP4, RAX/VSX2 (CHX10), SIX3/SIX6, HESX1 – Additional eye-patterning genes frequently screened. MedlinePlus

12. FREM1/FREM2/FRAS1 – Basement-membrane/craniofacial genes known in syndromic clefting with ocular anomalies. Breda Genetics

13. Chromosomal abnormalities – Copy-number changes can underlie MAC; microarray may detect these. ScienceDirect

14. Sporadic de novo variants – A new change in the child without parental history is common in MAC. MedlinePlus

15. Maternal vitamin A (retinoid) exposure – Excess (e.g., isotretinoin) or deficiency can disrupt eye formation. Cleveland Clinic

16. Maternal infections (e.g., rubella, CMV) – Recognized risks for severe eye malformations. Cleveland Clinic

17. Maternal diabetes? – Associated with a higher risk of major malformations including eye anomalies. Cleveland Clinic

18. Alcohol and certain teratogens – Have been linked to ocular maldevelopment. Cleveland Clinic

19. Multifactorial? mechanisms – Genes + environment acting together may explain many cases. Cleveland Clinic

20. Unknown/undetected genetic causes – Despite modern testing, a portion remains unexplained. MedlinePlus

Symptoms & signs

1. Absent or very small eyes → main feature; vision usually severely affected. NORD

2. Cleft lip and/or cleft palate → feeding and speech difficulties later; surgical repair is typical. Orpha

3. Wider facial clefts/frontonasal clefting in some babies; nose and central face may be split or very wide. PMC

4. Corneal clouding → the clear front window of the eye looks cloudy. PMC

5. Glaucoma → high pressure in the eye in some reports. PubMed

6. Coloboma → a “gap” in iris?/retina?/optic nerve? in some eyes. PubMed

7. Hypertelorism → eyes set widely apart. MalaCards

8. Ear anomalies/low-set ears → shape or position differences. MalaCards

9. Choanal atresia/stenosis? → blockage or narrowing behind the nose causing noisy breathing. MalaCards

10. Spinal/sacral defects → hemivertebrae, sacral agenesis, tethered cord in some cases. PubMed

11. Brain differences → under-developed corpus callosum or large ventricles? (hydrocephalus/ventriculomegaly). MalaCards

12. Endocrine problems → reported in some babies. MalaCards

13. Feeding/breathing difficulties in newborn period? due to clefts or airway anomalies. NORD

14. Developmental delay may occur, depending on brain/eye involvement and associated anomalies. gene.vision

15. General growth issues or multiple congenital anomalies across organs (kidneys/heart etc.) in subsets. MalaCards

Diagnostic tests

Physical examination

1. Newborn head-and-face exam – Doctor looks for eye size/shape, facial clefts, nose shape, ear position, and spacing of eyes to recognize the pattern. Orpha

2. Oral/palate check and feeding assessment? – Identifies cleft palate or difficulty sucking to guide early feeding support. Orpha

3. Airway and nasal exam – Checks for choanal atresia/stenosis causing noisy or obstructed breathing. MalaCards

4. Whole-body anomaly screen – Looks for spine, limb, genital, heart, and kidney? differences to document the full syndrome. MalaCards

Manual/clinical ophthalmic tests

5. External ocular exam & pupillary light response – Basic assessment of eye presence/size and light reaction. EyeWiki

6. Slit-lamp biomicroscopy (if possible) – Magnified view for corneal clouding, lens issues, and anterior segment structure. EyeWiki

7. Intraocular pressure (tonometry) – Screens for glaucoma when an eye is present. EyeWiki

8. Dilated fundus? exam – Looks for coloboma/retinal changes (where visualization is feasible). EyeWiki

9. Socket/soft-tissue assessment – For anophthalmia or severe microphthalmia, to plan early socket expansion with conformers. EyeWiki

Laboratory & pathological/genetic tests

10. Chromosomal microarray (CMA) – Detects small deletions/duplications that can cause MAC phenotypes. ScienceDirect

11. Targeted multigene panel for anophthalmia/microphthalmia – Tests dozens of eye-development genes (e.g., SOX2, OTX2, PAX6, ALDH1A3, STRA6, BCOR, CHD7, etc.). MedlinePlus

12. Whole-exome or whole-genome sequencing – Used when panel is negative to search broadly for a causative variant. (Testing guides list APS under ORPHA:1104 for selection.) Eurofins Biomnis Connect

13. Parental studies & segregation – Clarify whether a variant is inherited? (supports recessive/X-linked patterns) or new. MedlinePlus

14. Infectious disease labs (as indicated) – Congenital infections like CMV/rubella are checked if suspected. Cleveland Clinic

15. Metabolic or endocrine panels (as indicated) – When clinical signs suggest hormonal or metabolic involvement. MalaCards

Electrodiagnostic tests

16. Electroretinography (ERG) – Measures retinal function; often limited or absent in severe micro/anophthalmia but can document residual function. gene.vision

17. Visual evoked potentials (VEP) – Assesses the brain’s response to visual signals; helps when the eye exam is difficult. gene.vision

18. EEG? (if seizures) – Some babies with brain malformations may need seizure? evaluation. (General MAC care guidance.) gene.vision

Imaging tests

19. Prenatal? ultrasound and fetal MRI – May detect small or absent globes, facial clefts, and associated anomalies before birth. Orpha

20. Postnatal orbital ultrasound (B-scan) – Helps define the size/structure of the eye socket and any remnant eye tissue. EyeWiki

21. MRI of brain and orbits – Looks at optic nerves, brain structures (e.g., corpus callosum), ventricles, and midline defects. MalaCards

22. CT of facial bones/orbits (selected cases) – Maps bony anatomy for surgical planning in clefts or prosthetic fitting. EyeWiki

23. System screening imaging – e.g., echocardiogram, renal ultrasound, and spine imaging as guided by the physical exam. MalaCards

Non-pharmacological treatments (therapies & others)

How to read this section: each item gives an elaborate description (≈150 words), purpose, and mechanism in simple language. These are supportive, family-centered options used alongside medical and surgical care.

1. Multidisciplinary care pathway (NICU + specialty center)
   Description: Babies with Fryns features and eye malformations need a coordinated plan that links prenatal counseling, delivery, immediate breathing support, CDH management, and follow-up for feeding, growth, and development. Specialized centers use protocols for gentle ventilation, pulmonary hypertension monitoring, and timely surgery. A case manager helps coordinate neonatology, cardiology, pulmonology, surgery, ophthalmology/oculoplastics, genetics, rehab, nutrition, and social work. Family meetings review goals, procedures, and supports. Purpose: improve survival, reduce complications, and ensure families understand options. Mechanism: organized teamwork reduces delays, applies consistent evidence-based steps, and anticipates problems like reflux and oral aversion. BMJ Nutrition+1

2. Prenatal planning and delivery optimization
   Description: When CDH or severe anomalies are seen on ultrasound/MRI, families receive counseling about delivery at a tertiary center, possible fetal therapy (FETO) in select severe CDH cases, steroid timing, and neonatal resuscitation plans. Delivery room teams avoid bag-mask ventilation (which can worsen stomach inflation) and prepare for immediate intubation and gentle ventilation. Purpose: reduce lung injury at birth, optimize oxygen delivery, and line up early interventions. Mechanism: careful delivery protocols and, if applicable, FETO increase chances that hypoplastic lungs can adapt postnatally, while avoiding gastric insufflation and high airway pressures. Translational Pediatrics+1

3. Gentle ventilation strategies
   Description: After birth, gentle ventilation means using lower pressures, permissive carbon dioxide levels, and careful oxygen targets to protect fragile lungs. High-frequency ventilation may be used if conventional settings risk lung injury. Purpose: minimize ventilator-induced lung damage and support gas exchange while the baby stabilizes. Mechanism: lung-protective settings reduce over-distension and inflammation in hypoplastic lungs, improving short-term stability and readiness for surgery. UC Davis Health+1

4. Pulmonary hypertension monitoring and protocols
   Description: Many infants with CDH have high pressure in lung blood vessels (pulmonary hypertension). Teams use echocardiography, near-infrared spectroscopy, and standardized escalation steps. Purpose: promptly detect and treat pulmonary hypertension to maintain heart function and oxygen delivery. Mechanism: structured monitoring triggers timely support measures (e.g., ventilation adjustments, fluid balance, targeted medicines—see drug section). PMC+1

5. Timed surgical repair of the diaphragm (CDH repair)
   Description: Surgeons close the diaphragmatic defect after the infant is stabilized, sometimes with a patch for large defects. Purpose: restore separation of chest and abdomen, prevent abdominal organs from crowding the lungs/heart, and improve breathing mechanics. Mechanism: anatomical repair reduces lung compression and supports long-term respiratory function. BMJ Nutrition

6. Feeding therapy and nutrition support
   Description: Children with CDH often have reflux, oral aversion, and high calorie needs. Feeding therapists, dietitians, and gastroenterology create step-wise plans using thickened feeds, positional strategies, specialized formulas, or breastfeeding support. Purpose: ensure growth, reduce reflux symptoms, and improve feeding skills. Mechanism: smaller frequent feeds, thickening, and tailored formulas reduce reflux and aspiration risk while meeting energy needs. ScienceDirect+1

7. Reflux-focused behavioral and positional strategies
   Description: Non-drug steps include upright holding after feeds, careful burping, smaller volumes, and avoiding tight diapers. Purpose: reduce discomfort, vomiting, and aspiration risk. Mechanism: gravity and slower gastric filling lower reflux pressure events; parent coaching builds consistency at home. AAFP

8. Early ocular-socket expansion with clear conformers
   Description: For anophthalmia/microphthalmia, oculoplastic teams place small clear shells (“conformers”) that are gradually upsized to stimulate eyelid and socket growth; the clear design lets doctors monitor any tiny eye tissue. Purpose: promote symmetrical facial growth and prepare for a prosthetic eye. Mechanism: gentle mechanical expansion guides soft-tissue growth during infancy when tissues are most adaptable. Nature

9. Custom ocular prosthesis and progressive expansion
   Description: After sufficient socket growth, a custom ocular prosthesis is fitted; periodic enlargement maintains symmetry. Purpose: improve cosmesis, eyelid function, tear film distribution, and psychosocial wellbeing. Mechanism: prosthetic volume replaces the absent eye, supporting orbital bone and soft-tissue development. PMC+1

10. Socket surgery if needed (conjunctival sac/palpebral fissure)
    Description: When soft tissues are too tight, minor procedures enlarge the socket or eyelid opening to accept conformers/prosthesis. Purpose: enable proper prosthetic fit and comfort. Mechanism: surgical release increases space and reduces scarring, improving prosthetic retention. PMC+1

11. Vision habilitation and developmental therapies
    Description: Even with little or no vision, early orientation-and-mobility training, tactile exploration, and communication tools (including early intervention services) support development. Purpose: maximize functional independence and learning. Mechanism: neuroplasticity and adapted skills compensate for visual loss, improving milestones. BioMed Central

12. Respiratory physiotherapy and airway clearance
    Description: Gentle airway clearance and positioning can help some infants with ongoing lung vulnerability after CDH repair. Purpose: reduce atelectasis and infections. Mechanism: targeted techniques optimize ventilation-perfusion and mucus clearance in hypoplastic lungs. BMJ Nutrition

13. Cardiorespiratory monitoring at home (as indicated)
    Description: Selected infants go home with simple monitors or oxygen plans. Purpose: detect desaturation events and support safe growth. Mechanism: continuous or spot checks prompt timely clinical review if instability occurs. BMJ Nutrition

14. Family psychosocial support and counseling
    Description: Social workers and psychologists address stress, grief, complex decision-making, and expectations. Purpose: sustain caregiver wellbeing and informed choices. Mechanism: structured counseling improves coping and adherence to care plans. BMJ Nutrition

15. Genetic counseling and cascade testing
    Description: Families learn inheritance patterns (often autosomal recessive), recurrence risks, and options for future pregnancies. Purpose: empower planning and connect families to research when appropriate. Mechanism: explaining the role of genes (e.g., PIGN or eye-development genes) informs reproductive decisions. PMC+1

16. Hearing screening and early audiology care
    Description: Syndromic eye conditions can accompany ear differences; early screening catches hearing loss that would compound developmental delay. Purpose: protect speech and learning. Mechanism: prompt amplification or therapy reduces language delay. BioMed Central

17. Dental and craniofacial follow-up
    Description: Orofacial clefts or facial differences need coordinated dental/ENT/craniofacial review. Purpose: support feeding, speech, and facial growth. Mechanism: staged dental and surgical planning optimizes function and appearance. Wiley Online Library

18. Early intervention (physio/OT/speech)
    Description: Structured therapies address hypotonia, fine motor, or oral-motor challenges. Purpose: improve motor skills, feeding, and communication. Mechanism: repetitive, goal-directed practice builds strength, coordination, and safe swallow. AAP Publications

19. School vision services and assistive technology
    Description: As children grow, low-vision services, tactile learning tools, and mobility training are arranged. Purpose: educational access and safety. Mechanism: accommodations and devices offset sensory limits to support learning. BioMed Central

20. Transition-to-adulthood planning (for survivors)
    Description: Teens and families plan transfer to adult providers for lungs, heart, GI, and prosthetic care, plus vocational and psychosocial support. Purpose: preserve continuity of care and independence. Mechanism: structured handoff reduces health gaps and maintains prosthetic and reflux management. PMC

Drug treatments

Note: There is no disease-modifying drug for Fryns microphthalmia syndrome. Medicines are individualized by specialists for CDH-related lung disease, pulmonary hypertension, reflux, seizures, infections, pain, and nutrition. Doses are weight-based and protocol-driven in neonates/children; exact dosing must follow local guidelines. The list below explains common categories used in care; your team selects and titrates therapy. BMJ Nutrition+1

1. Inhaled nitric oxide (iNO) — Pulmonary vasodilator; NICU protocol dosing
   Long description (≈150 words): iNO relaxes smooth muscle in lung blood vessels, lowering pressure and improving oxygenation in selected infants with pulmonary hypertension after CDH. It is delivered through the ventilator circuit and adjusted based on oxygenation, echocardiography, and potential methemoglobinemia risk. Class: selective pulmonary vasodilator gas. Dosage/Time: protocolized, continuous inhalation in NICU. Purpose: reduce right-to-left shunting and improve oxygen delivery. Mechanism: activates guanylate cyclase via nitric oxide, raising cGMP in pulmonary vasculature, causing vasodilation. Side effects: methemoglobinemia, rebound PH if abruptly stopped. Nature

2. Sildenafil — Phosphodiesterase-5 inhibitor
   Helps manage persistent pulmonary hypertension by preventing cGMP breakdown, complementing or following iNO. Pediatric dosing is specialist-directed (oral/IV). Possible side effects: hypotension, flushing. Nature

3. Milrinone — Phosphodiesterase-3 inhibitor/inodilator
   Sometimes used when heart function and pulmonary pressures are both concerns; improves cardiac output and causes vasodilation. Side effects include arrhythmias and hypotension; dosing is ICU-titrated. Nature

4. Prostaglandin analogs (e.g., epoprostenol/iloprost—specialist use)
   Used in selected pulmonary hypertension scenarios as vasodilators; routes and dosing are specialist-controlled due to potency. Side effects: hypotension, flushing, jaw pain (depending on agent). Nature

5. Gentle sedation/analgesia (e.g., morphine/fentanyl per protocol)
   Used briefly to improve ventilator synchrony and reduce stress; dosing is cautious to avoid respiratory depression and withdrawal. BMJ Nutrition

6. Diuretics (e.g., furosemide)
   For fluid management in lung disease or heart strain; reduces pulmonary edema risk. Watch electrolytes and kidney function. BMJ Nutrition

7. Vasoactive support (e.g., norepinephrine/vasopressin—ICU use)
   Supports blood pressure and organ perfusion if hypotension occurs during critical illness; titrated in ICU with continuous monitoring. BMJ Nutrition

8. Surfactant (case-by-case)
   In some centers, exogenous surfactant may be considered if clinical indicators suggest surfactant deficiency; decisions are individualized. BMJ Nutrition

9. Proton-pump inhibitors (PPIs)
   For significant GERD documented in CDH survivors; aim to protect esophagus and reduce pain/vomiting with reflux. Side effects include altered microbiome and, with chronic use, possible nutrient effects—therapy is periodically reassessed. jpedsurg.org

10. H2-receptor blockers
    An alternative or bridge for reflux control when PPIs are not preferred; dosing is pediatric-specific. Side effects may include tachyphylaxis. AAFP

11. Prokinetics (selected cases)
    In difficult GERD/feeding cases, specialist may trial a prokinetic agent to improve gastric emptying; careful risk-benefit and monitoring are required. AAFP

12. Thickening agents/formula modifications (adjunct to meds)
    Although not “drugs,” thickening strategies often accompany reflux regimens; listed here to emphasize combined approaches under supervision. AAFP

13. Antiemetics (short-term)
    Used sparingly for distressing vomiting while the underlying reflux and feeding plan is optimized. AAFP

14. Antibiotics (treat infections only)
    CDH survivors may be infection-prone; antibiotics target proven bacterial infections and should not be used for uncomplicated reflux. BMJ Nutrition

15. Anticonvulsants (e.g., levetiracetam)
    Used if a child with Fryns features develops seizures from brain malformations or hypoxia; agent choice and dosing are individualized to EEG and age. NCBI

16. Bronchodilators (selected reactive airway cases)
    Some survivors have reactive airway symptoms; bronchodilators are trialed based on response, not routinely. BMJ Nutrition

17. Inhaled corticosteroids (selected cases)
    For persistent airway inflammation with symptoms; specialist-guided, with growth and side-effect monitoring. BMJ Nutrition

18. Nutritional pharmacotherapy (e.g., medium-chain triglyceride formulas—adjunct)
    Special formulas may be used under dietitian direction to meet high caloric needs and reduce reflux burden. ScienceDirect

19. Pulmonary vasodilator transition regimens (outpatient)
    Some children transition from NICU vasodilators to oral agents during follow-up; careful weaning prevents rebound PH. Nature

20. Vaccinations and RSV/viral prophylaxis as eligible
    Immunizations and, when criteria are met, seasonal monoclonal antibody prophylaxis reduce respiratory infections that destabilize fragile lungs. BMJ Nutrition

Dietary molecular supplements

Note: Supplements do not treat the genetic cause but may support growth when guided by a clinician/dietitian. Always check interactions and suitability for infants/children.

1. Energy-dense formula modulars (e.g., MCT oil modular) — helps meet high energy needs without large volumes; mechanism: easier fat absorption and more calories per milliliter. ScienceDirect

2. Thickening starches or gums — reduce reflux by increasing feed viscosity; mechanism: slower gastric emptying and fewer regurgitation events. AAFP

3. Hydrolyzed or amino-acid formulas — for suspected cow-milk protein sensitivity worsening reflux/feeding; mechanism: reduced antigenicity and improved tolerance. AAFP

4. Vitamin D — supports bone health and general growth in children with limited outdoor activity or feeding challenges. AAP Publications

5. Iron (if deficient) — addresses iron deficiency from prematurity/illness; mechanism: restores hemoglobin and supports development. AAP Publications

6. Calcium/phosphate (if low) — supports bone mineralization with chronic illness or PPI use; monitored to avoid imbalance. AAP Publications

7. Omega-3 fatty acids (age-appropriate formulations) — may help overall nutrition; mechanism: essential fatty acids for growth and cell membranes. AAP Publications

8. Probiotics (selected cases) — sometimes considered for reflux/feeding programs; mechanism: microbiome modulation (evidence mixed; clinician-guided). AAFP

9. Electrolyte supplements (as indicated) — replace losses with diuretics or illness; mechanism: maintain cardiac/neuromuscular function. BMJ Nutrition

10. Micronutrient multivitamin (age-appropriate) — supports general needs when intake is borderline; mechanism: covers common gaps during complex feeding plans. AAP Publications

Drugs for immunity booster / regenerative / stem-cell

There are no proven immune-booster or regenerative/stem-cell drugs that correct Fryns microphthalmia syndrome. Care focuses on prevention of infection and protecting fragile lungs. Below are the practical, ethical “immunity-support” measures clinicians actually use in this setting. BMJ Nutrition

1. Routine vaccinations (per schedule) — dosage and timing per national program; function: prevent common infections that would worsen lung disease. Mechanism: active immunity via antigen exposure. BMJ Nutrition

2. Monoclonal antibody prophylaxis for RSV (seasonal, if eligible) — dosage per weight/season protocol; function: passive immunity to reduce RSV hospitalization in high-risk infants. Mechanism: neutralizes RSV F protein. BMJ Nutrition

3. Nutritional optimization (prescribed calories/protein, see diet section) — not a drug, but the most effective “immune support”; mechanism: adequate substrate for immune cells and healing. ScienceDirect

4. Pulmonary vasodilator stewardship (e.g., sildenafil) to maintain lung health — dosage protocolized; function: reduces PH episodes that predispose to decompensation during infections. Mechanism: pulmonary vascular cGMP pathway. Nature

5. Vitamin D supplementation (if deficient) — dosage per pediatric guidelines; function: supports immune modulation and bone health; mechanism: vitamin-D receptor signaling in immune cells. AAP Publications

6. No stem-cell therapy recommended — investigational stem-cell products are not standard for Fryns or AMC and should only be used within regulated trials; mechanism claims are unproven here. BioMed Central

Surgeries

1. Diaphragmatic hernia repair — Close the hole and return abdominal organs to abdomen; why: improve breathing mechanics and protect heart/lungs from compression. BMJ Nutrition

2. Eye-socket (conjunctival sac) expansion / eyelid surgery — Create room for conformers/prosthesis; why: promote symmetric facial/orbital growth and comfortable prosthetic wear. PMC

3. Gastrostomy tube (G-tube) placement (selected) — Provide reliable nutrition when oral feeding is unsafe/insufficient; why: support growth and reduce aspiration. ScienceDirect

4. Anti-reflux surgery (e.g., Nissen fundoplication in refractory cases) — Tighten the lower esophageal sphincter mechanism; why: control severe GERD causing pain, poor growth, or aspiration. jpedsurg.org

5. Cleft lip/palate repair (if present) — Reconstruct anatomy for feeding and speech; why: improve nutrition, reduce ear problems, and support language development. Wiley Online Library

Preventions

1. Deliver and treat in an experienced center to apply standardized, evidence-based CDH protocols. ScienceDirect

2. Prenatal counseling and planning to reduce delivery-room risks. Translational Pediatrics

3. Avoid bag-mask ventilation at birth in known/suspected CDH to limit gastric insufflation. CMAJ

4. Follow reflux-reducing feeding strategies early. AAFP

5. Keep vaccines up to date to prevent respiratory infections. BMJ Nutrition

6. Early prosthetic/conformer program to guide socket growth. Nature

7. Scheduled echo and PH follow-ups for timely treatment adjustments. Nature

8. Nutrition and growth monitoring with a dietitian. ScienceDirect

9. Early hearing/vision-related developmental support to protect milestones. BioMed Central

10. Family mental-health and social support to sustain long-term care consistency. BMJ Nutrition

When to see doctors

Seek medical help immediately if a child with Fryns features or CDH history has fast or difficult breathing, bluish skin, poor feeding, repeated vomiting with poor weight gain, fainting or unusual sleepiness, a new seizure, fever with breathing trouble, or if the prosthetic eye/socket becomes very painful, red, or dislodged. These signs can mean worsening lung hypertension, infection, dehydration, or socket complications that need urgent review. Routine visits should include pulmonology/cardiology (for PH), surgery (for CDH repair follow-up), gastroenterology/nutrition (for reflux/growth), ophthalmology/oculoplastics (for conformer/prosthesis changes), audiology, and developmental services. Nature+2jpedsurg.org+2

What to eat / what to avoid

1. Prefer small, frequent feeds and avoid overfilling the stomach. AAFP

2. Use thickened feeds when advised to cut regurgitation. AAFP

3. Consider hydrolyzed or amino-acid formulas if protein intolerance worsens reflux. AAFP

4. Hold upright after feeds; avoid lying flat immediately. AAFP

5. Work with a dietitian to reach calorie targets with acceptable volumes (e.g., modulars). ScienceDirect

6. Avoid large, spicy, very fatty meals (for older children) that can trigger reflux. AAFP

7. Limit carbonated drinks and late-evening meals (age-appropriate). AAFP

8. Support breastfeeding with lactation guidance when possible. PubMed

9. Ensure vitamins/minerals per pediatric guidance if intake is borderline. AAP Publications

10. Reassess diet as growth changes, because needs evolve quickly in infancy and early childhood. ScienceDirect

FAQs

1) Is Fryns microphthalmia syndrome genetic?
Usually yes. Classic Fryns is typically autosomal recessive; PIGN variants explain a Fryns-like picture in some families. Eye malformations (AM/Microphthalmia) involve many genes; testing helps clarify recurrence risk. NCBI+1

2) Can medicines cure Fryns syndrome or anophthalmia?
No. Treatments support breathing, feeding, growth, and socket development; there is no curative drug for the overall syndrome. NCBI

3) What determines survival?
Lung development and severity of the diaphragmatic defect are key; associated organ anomalies also matter. Care at experienced centers helps. BMJ Nutrition

4) What is FETO and who qualifies?
A fetal endoscopic balloon temporarily occludes the trachea in severe CDH to stimulate lung growth; used in very selected cases after specialist assessment. Translational Pediatrics

5) Why avoid bag-mask ventilation at birth?
It inflates the stomach/bowel, worsening chest compression in CDH; early intubation is preferred. CMAJ

6) How is pulmonary hypertension treated?
With careful ventilation and targeted vasodilators like iNO or sildenafil under strict protocols, plus echocardiography-guided adjustments. Nature

7) Why is feeding so hard?
GERD and oral aversion are common after CDH; energy needs are high and volumes must be balanced—hence dietitian-led plans and reflux care. jpedsurg.org

8) Can eye size be increased?
Yes—progressive conformers and custom prostheses expand the socket and support facial symmetry; sometimes minor socket surgery is needed. Nature+1

9) Will my child ever see from the affected eye?
With true anophthalmia there is no eye to see; with microphthalmia, vision varies based on internal structures. Early low-vision support maximizes function. BioMed Central

10) Do all families need genetic testing?
Testing is strongly advised to clarify cause, guide counseling, and connect to research or support groups. PMC

11) Are there stem-cell treatments for this?
No approved stem-cell therapy exists for Fryns or AMC; avoid unregulated offerings outside trials. BioMed Central

12) What is the long-term outlook?
Varies widely; some infants have critical lung disease, while others survive with ongoing feeding, reflux, and developmental needs requiring long-term follow-up. Genetic Diseases Center

13) Will my child need multiple surgeries?
Possibly—CDH repair is common; some need G-tube or anti-reflux surgery; some need socket/eyelid procedures and cleft repair if present. BMJ Nutrition+2jpedsurg.org+2

14) How often are eye prostheses adjusted?
Regularly during growth; the team enlarges or refits as the face changes to maintain symmetry and comfort. PMC

15) Where can I read more?
GeneReviews (Fryns), MedlinePlus, GARD/NORD summaries, and recent AMC management reviews are trustworthy starting points; clinicians can share center-specific protocols. NCBI+2MedlinePlus+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 19, 2025.